Companies › Hangzhou Sciwind Biosciences
3 active drug programs in 5 registered trials: 3 Phase 3, 1 Phase 1, 1 Phase 2; Metabolic and endocrine, Respiratory, Immunology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XW003 injection GLP-1 receptor agonist | GLP1R | Phase 3 | OSA - Obstructive Sleep Apnea; Obesity | Feb 2027 |
| Econoglutide Injection GLP-1 receptor agonist | GLP1R | Phase 3 | Knee Osteoarthritis | May 2028 |
| ecnoglutide tablets GLP-1 receptor agonist | GLP1R | Phase 1 | Overweight and/or Obesity | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07243171 | ecnoglutide tablets | Phase 1 | Overweight and/or Obesity | Metabolic and endocrine | Jan 2027 |
| NCT07073417 | XW003 injection | Phase 2 | Obesity | Metabolic and endocrine | Feb 2027 |
| NCT07387094 | XW003 injection | Phase 3 | OSA - Obstructive Sleep Apnea | Respiratory | Dec 2027 |
| NCT07734311 | Econoglutide Injection | Phase 3 | Knee Osteoarthritis | Immunology | May 2028 |
| NCT07434050 | XW003 injection | Phase 3 | OSA - Obstructive Sleep Apnea | Respiratory | Jun 2028 |
Kailera Mediar Therapeutics Beijing QL Biopharmaceutical Beijing Dongfang Biotech Chendu DIAO Pharmaceutical Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.